However, several logistical and economic barriers hinder its widespread use, including the requirement for fresh tumor tissue, the labor-intensive process of generating and expanding TILs with IL-2, anti-CD3, and feeder cells, and the eventual reinfusion into the patient [117]. Here, IL2 is linked to neoplasm.